Stifel Nicolaus reiterates its Buy rating for Apple AAPL and Endo Pharmaceuticals ENDP and has raised the price targets from $350 to $360 and from $30 to $43, respectively.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Price TargetInitiationAnalyst RatingsAppleComputer Hardwareendo pharmaceuticalsHealth CareInformation TechnologyPharmaceuticalsStifel Nicolaus
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
